314:
624:
29:
480:
Marimastat performed poorly in clinical trials, and development was terminated. This may be, however, a result of targeting cancer at too late of a stage. This is supported by the fact that MMP inhibitors have more recently been shown in animal models to be more effective in earlier stages of
579:"Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196"
387:
721:
481:
cancers. (Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and
Hanahan, D. (1999)).
55:
445:
672:
706:
401:
429:
InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
691:
665:
696:
474:
658:
421:
530:"Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers"
100:
76:
716:
225:
711:
293:
701:
514:
174:
41:
254:
165:
577:
Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE (December 2004).
309:
638:
120:
48:
275:
600:
559:
265:
642:
590:
549:
541:
528:
Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP (January 1998).
330:
214:
129:
234:
635:
470:
313:
631:
554:
529:
466:
685:
545:
510:
154:
623:
490:
363:
205:
595:
578:
604:
20:
563:
185:
194:
140:
28:
245:
386:
377:
281:
298:
646:
452:
375:
362:
329:
324:
292:
264:
244:
224:
204:
184:
173:
164:
139:
119:
91:
75:
70:
54:
40:
35:
153:
128:
722:Antineoplastic and immunomodulating drug stubs
666:
8:
19:
673:
659:
312:
213:
27:
594:
553:
409:O=C(NO)(O)(C(=O)N(C(=O)NC)C(C)(C)C)CC(C)C
233:
534:British Journal of Clinical Pharmacology
502:
426:
406:
308:
193:
105:
18:
274:
253:
7:
620:
618:
280:
707:Matrix metalloproteinase inhibitors
144:
645:. You can help Knowledge (XXG) by
475:matrix metalloproteinase inhibitor
14:
622:
546:10.1046/j.1365-2125.1998.00639.x
347:
341:
473:. It acted as a broad-spectrum
434:Key:OCSMOTCMPXTDND-OUAUKWLOSA-N
692:Drugs not assigned an ATC code
353:
335:
1:
583:Journal of Clinical Oncology
738:
617:
325:Chemical and physical data
111:--2--4- methyl-pentanamide
697:Experimental cancer drugs
515:National Cancer Institute
442:
417:
397:
96:
26:
596:10.1200/JCO.2004.08.054
84:Development terminated?
717:Tert-butyl compounds
23:
712:Isobutyl compounds
469:drug developed by
654:
653:
460:
459:
388:Interactive image
294:CompTox Dashboard
16:Chemical compound
729:
702:Hydroxamic acids
675:
668:
661:
636:immunomodulatory
626:
619:
609:
608:
598:
574:
568:
567:
557:
525:
519:
518:
507:
456:
455:
448:
390:
370:
355:
349:
343:
337:
317:
316:
302:
300:
284:
278:
257:
237:
217:
197:
177:
157:
147:
146:
132:
31:
24:
22:
737:
736:
732:
731:
730:
728:
727:
726:
682:
681:
680:
679:
615:
613:
612:
589:(23): 4683–90.
576:
575:
571:
527:
526:
522:
509:
508:
504:
499:
487:
471:British Biotech
465:was a proposed
451:
449:
446:(what is this?)
443:
438:
435:
430:
425:
424:
413:
410:
405:
404:
393:
368:
358:
352:
346:
340:
320:
296:
288:
260:
240:
220:
200:
180:
160:
143:
135:
115:
112:
104:
103:
87:
66:
43:
17:
12:
11:
5:
735:
733:
725:
724:
719:
714:
709:
704:
699:
694:
684:
683:
678:
677:
670:
663:
655:
652:
651:
632:antineoplastic
627:
611:
610:
569:
520:
501:
500:
498:
495:
494:
493:
486:
483:
467:antineoplastic
458:
457:
440:
439:
437:
436:
433:
431:
428:
420:
419:
418:
415:
414:
412:
411:
408:
400:
399:
398:
395:
394:
392:
391:
383:
381:
373:
372:
366:
360:
359:
356:
350:
344:
338:
333:
327:
326:
322:
321:
319:
318:
310:DTXSID20165524
305:
303:
290:
289:
287:
286:
270:
268:
262:
261:
259:
258:
250:
248:
242:
241:
239:
238:
230:
228:
222:
221:
219:
218:
210:
208:
202:
201:
199:
198:
190:
188:
182:
181:
179:
178:
170:
168:
162:
161:
159:
158:
150:
148:
137:
136:
134:
133:
125:
123:
117:
116:
114:
113:
107:
99:
98:
97:
94:
93:
89:
88:
86:
85:
81:
79:
73:
72:
68:
67:
65:
64:
60:
58:
52:
51:
46:
44:administration
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
734:
723:
720:
718:
715:
713:
710:
708:
705:
703:
700:
698:
695:
693:
690:
689:
687:
676:
671:
669:
664:
662:
657:
656:
650:
648:
644:
641:article is a
640:
637:
633:
628:
625:
621:
616:
606:
602:
597:
592:
588:
584:
580:
573:
570:
565:
561:
556:
551:
547:
543:
539:
535:
531:
524:
521:
516:
512:
506:
503:
496:
492:
489:
488:
484:
482:
478:
476:
472:
468:
464:
454:
447:
441:
432:
427:
423:
416:
407:
403:
396:
389:
385:
384:
382:
379:
374:
367:
365:
361:
334:
332:
328:
323:
315:
311:
307:
306:
304:
295:
291:
283:
282:RCSB PDB
277:
272:
271:
269:
267:
263:
256:
252:
251:
249:
247:
243:
236:
232:
231:
229:
227:
223:
216:
212:
211:
209:
207:
203:
196:
192:
191:
189:
187:
183:
176:
172:
171:
169:
167:
163:
156:
152:
151:
149:
142:
138:
131:
127:
126:
124:
122:
118:
110:
106:
102:
95:
90:
83:
82:
80:
78:
74:
69:
62:
61:
59:
57:
53:
50:
47:
45:
39:
36:Clinical data
34:
30:
25:
647:expanding it
629:
614:
586:
582:
572:
537:
533:
523:
511:"Marimastat"
505:
479:
462:
461:
450:
444:
255:ChEMBL279785
108:
77:Legal status
71:Legal status
540:(1): 21–6.
371: g·mol
130:154039-60-8
92:Identifiers
686:Categories
497:References
491:Batimastat
463:Marimastat
376:3D model (
364:Molar mass
266:PDB ligand
235:D5EQV23TDS
206:ChemSpider
166:IUPHAR/BPS
121:CAS Number
101:IUPAC name
21:Marimastat
42:Routes of
605:15570070
485:See also
453:(verify)
186:DrugBank
56:ATC code
49:By mouth
564:9489589
555:1873993
369:331.413
331:Formula
195:DB00786
141:PubChem
603:
562:
552:
402:SMILES
246:ChEMBL
215:106358
155:119031
630:This
422:InChI
378:JSmol
273:097 (
643:stub
639:drug
601:PMID
560:PMID
276:PDBe
226:UNII
175:5220
63:None
634:or
591:doi
550:PMC
542:doi
299:EPA
145:CID
688::
599:.
587:22
585:.
581:.
558:.
548:.
538:45
536:.
532:.
513:.
477:.
345:29
339:15
279:,
674:e
667:t
660:v
649:.
607:.
593::
566:.
544::
517:.
380:)
357:5
354:O
351:3
348:N
342:H
336:C
301:)
297:(
285:)
109:N
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
